← All trials
NCT04840641
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2021
- Primary completion
- Dec 31, 2021
- Completion date
- Jan 14, 2022
- First posted
- Apr 12, 2021
- Last posted
- Apr 12, 2021
- Enrollment
- 14
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Southern DenmarkLead sponsor
- SignaTope GmbH, GermanyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.